| HOME >> BIOLOGY >> TECHNOLOGY |
PHARMATHENE, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Three months ended Nine months ended
September 30, September 30,
2009 2008 2009 2008
---- ---- ---- ----
Contract revenue $6,830,399 $10,643,705 $20,423,513 $27,377,207
Other revenue - 32,461 - 53,612
--- ------ --- ------
6,830,399 10,676,166 20,423,513 27,430,819
Operating expenses:
Research and
development 7,609,794 9,414,093 22,769,749 26,475,436
General and
administrative 6,224,868 4,803,190 15,787,115 14,655,971
Acquired in-process
research and
development - 225,000 - 16,131,002
Depreciation and
amortization 247,747 205,409 639,924 641,425
Other expenses 274,005 - 1,158,566 -
---------- ---------- ---------- ----------
Total operating
expenses 14,356,414 14,647,692 40,355,354 57,903,834
'/>"/>
| SOURCE PharmAthene, Inc. Copyright©2009 PR Newswire. All rights reserved |